Bausch & Lomb Ireland withdraws its marketing authorisation application for Retisert

View source ↗

Summary

Bausch & Lomb Ireland has withdrawn its marketing authorisation application for Retisert (fluocinolone acetonide intravitreal implant).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Noninfectious Uveitis Affecting the Posterior Segment of the Eye

Drugs mentioned

• Retisert (fluocinolone acetonide)